TP53 mutated MDS and AML represent some of the most difficult diseases to treat, with poor prognosis. Although allogeneic stem cell transplant has the potential to cure myeloid malignancies, cure rates in TP53 mutated disease are low, and the utility of transplant for such patients is controversial. In this webinar, we will use a case based approach to debate the best transplant approach (including no transplant) for older patients with TP53 mutated disease in different scenarios. 

Presented by the ASTCT Aging SIG

Speakers:

Mariam Nawas, MD, University of Chicago Medical Center 
Pashna Munshi, MD, University of Pennsylvania
Mohamed Sorror, MD, Fred Hutchinson Cancer Center
Jackie Garcia, MD, Dana-Farber Cancer Institute
Mikkael Sekeres, MD, University of Miami

Moderator:

Rebecca Olin, MD MSCE, University of California San Francisco

Join the ASTCT Committee on Education and Content on Wednesday, September 2, from 12:00-1:00 p.m. CT (1:00-2:00 p.m. ET) for an engaging case discussion featuring a multidisciplinary panel, including a pediatric hematologist, radiologist, and pulmonologist. Panelists will share how they collaborate to evaluate and solve a complex clinical case.

This session is designed for and open to all members of a multidisciplinary care team to attend.

Learning Objectives
• Recognize bronchiectasis as a potential manifestation of chronic pulmonary GVHD/bronchiolitis obliterans syndrome (BOS).
• Interpret imaging and pulmonary function findings in the context of chronic lung GVHD.
• Discuss therapeutic challenges in refractory pulmonary chronic GVHD and explore emerging treatment strategies.

Speakers
• Gregory Burg, MD; Cincinnati Children's Hospital, Department of Pulmonology
• Paul Guillerman, MD: Cincinnati Children's Hospital, Department of Radiology
• Pooja Khandelwal, MD: Cincinnati Children's Hospital, Department of Pediatric Hematology

Join the ASTCT Pharmacy SIG on Tuesday, August 25 from 2-3 p.m. CT/3-4 p.m. ET for an interactive session featuring a multidisciplinary panel that includes a nurse, advanced practice providers (APPs), and pharmacists discussing therapy sequencing strategies for chronic graft-versus-host disease (cGVHD). Through expert dialogue and case-based scenarios, panelists will share real-world approaches, discuss challenges in treatment selection and sequencing, and explore considerations across diverse patient populations and practice settings. If you have a question for the discussion, feel free to submit them here by August 10th.

This session is designed for nursing, APP, and pharmacy professionals. This webinar provides an opportunity to learn from peers, exchange perspectives, and engage in open discussion on the evolving management of cGVHD.

Panelists:

Brooke Adams, PharmD, BCOP; Orlando Health

Nancy Austin, BSN, RN, BMTCN; Duke University

Jean Caputo, APRN; The Ohio State University  

Alexis Kuhn, PharmD, BCOP; Mayo Clinic

Christina Luszcak, PharmD, BCOP; University Hospitals - Cleveland Medical Center

Anand Patel, PharmD, BCPS; Atrium Health Wake Forest Baptist

Jenna Schmitz, DNP, APRN, FNP-C; Moffitt Cancer Center

Please join Director of Government Relations, Molly Ford, and the reimbursement and policy advisors from Nimitt Consulting for the Medicare Rules Round-up Webinar on Wednesday, August 19, 2026 from 11:00 a.m. – 12:00 p.m. CDT

The OPPS and MPFS proposed rules were released on July 7 and July 16, respectively. ASTCT will be circulating draft comments to CMS in advance of the comment period closing.  Comments can be submitted to CMS via https://www.regulations.gov and are due by August 31 (OPPS) and September 14 (MPFS).

The IPPS final rule was issued on July 31 and goes into effect on October 1, 2026.  A few payment highlights include the following:

• Overall payments were increased by 2.3%
• The base payment for MS-DRG 014 (Allogeneic Stem Cell Transplant) decreased slightly from FY 2026 to $87,109
• The base payment for MS-DRG 018 (CAR-T and Other Immunotherapies) has increased by almost $20,000 to $333,445
• The outlier fixed loss threshold has increased to $49,346 per MS-DRG, up from $40,397

There will be a Q&A section at the end of the webinar, so please register and submit any questions in advance that you would like answered during the webinar to [email protected]. If you are unable to join, the recording will be made available. 

Please consider sharing this webinar information with your network of physicians, administrators, providers, or any other colleagues that may be interested.

The Cord Blood as Graft of Choice for Difficult-to-Cure Acute Leukemia webinar, presented by the ASTCT Cord Blood SIG, aired on Wednesday, July 1 at 11 a.m. CT/12 p.m. ET. The speakers participated in a moderated roundtable discussion, focusing on the state-of-the-art in cord blood transplantation in high-risk disease settings, the future research and work needed.

Session Description:

The Cord blood transplantation is associated with robust graft-versus-leukemia effect, and recent data from centers with cord blood transplantation expertise have shown outstanding post-transplant outcomes, including for patients with high-risk hematologic malignancies. This webinar continues the conversation following a spotlight session hosted by the ASTCT Cord Blood SIG at Tandem 2026 on the cord blood transplantation for patients with high risk hematologic malignancies. The session will review cord blood transplantation outcome data from multiple institutions across three continents and with different patient populations, highlighting the special value of cord blood transplantation in adult and pediatric patients to mitigate disease relapse and improve transplant outcomes. The speakers will participate in a moderated roundtable discussion, focusing on the state-of-the-art in cord blood transplantation in high-risk disease settings, the future research and work needed.

Presenters:

Juliet Barker, MBBS

New York-Presbyterian/Weill Cornell Medical Center; New York City, NY

Filippo Milano, MD, PhD

Fred Hutchinson Cancer Center, University of Washington; Seattle, WA

Robert Wynn, MD, MRCP

Royal Manchester Children's Hospital; Manchester, UK

Moderator:

Warren Fingrut, MD, MPH

The University of Texas MD Anderson Cancer Center; Houston, TX

Session Learning Objectives:

Upon completion of the activity, participants should be able to:

• Understand the indications for cord blood transplantation
• Synthesize cord blood transplantation outcomes data, including in high risk disease settings, from multiple centers with cord blood transplantation expertise
• Review translational work underlying the unique graft-versus-leukemia biology in cord blood transplantation.

The ASTCT Pharmacy SIG June 2026 Journal Club aired on Wednesday, June 10. The webinar consisted of two, 30-minute journal club presentations, which included 20 minutes for the presentation and 10 minutes for discussion and a Q & A session. In the June Journal Club session, Drs. Dugas and Kanchan will presented two articles related to:

• Brexucabtagene autoleucel in BTKi‑naive relapsed/refractory mantle cell lymphoma
• Carfilzomib, lenalidomide, and dexamethasone vs lenalidomide maintenance post‑transplant in multiple myeloma

Presenters & Articles:

Logan Dugas, PharmD

PGY-2 Pharmacy Resident

Moffitt Cancer Center

Article: Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial

Nidhi Kanchan, PharmD

PGY-2 Pharmacy Resident

UC San Diego Health

Article: Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 cohort 3

Session Learning Objectives:

Upon completion of the activity, participants should be able to:

• Recognize post-ASCT maintenance strategies that have been studied in multiple myeloma.
• Report efficacy and safety of KRd as a risk-stratified maintenance approach.
• Discuss the application of KRd maintenance following transplant in newly diagnosed multiple myeloma.
• Review current treatment recommendations and sequencing of therapy for relapsed/refractory mantle cell lymphoma, including the role of BTK inhibitors.
• Evaluate safety and efficacy of brexucabtagene autoleucel in BTKi-naive patients with relapsed/refractory mantle cell lymphoma based on the primary analysis of ZUMA-2 Cohort 3.
• Summarize the role of brexucabtagene autoleucel in earlier lines of therapy for patients with high-risk relapsed/refractory mantle cell lymphoma.

This activity will expire on June 9, 2027.

ACCREDITED PROVIDER

This activity is jointly provided by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT).

In support of improving patient care, this activity has been planned and implemented by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT). The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CREDIT DESIGNATION

Pharmacists

This knowledge-based activity qualifies for 1.0 contact hour (0.10 CEU) of continuing pharmacy education credit. Please submit all evaluations and credit requests no later than 30 days after you complete this activity to ensure your credit fulfillment, as CE credit cannot be awarded past 60 days from the activity date. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service ([email protected]). 

All other healthcare professionals completing this course will be issued a statement of participation.

The full accreditation information for this session can be found here. 

Severe aplastic anemia (SAA) is a life-threatening bone marrow failure disorder characterized by pancytopenia and hypocellular
marrow. Over the past two decades, advances in donor selection, conditioning regimens, supportive care, and graft-versus-host
disease prophylaxis have significantly improved transplant outcomes, leading to renewed consideration of upfront bone marrow
transplantation (BMT) as first-line therapy for selected patients.

This session will review the pathophysiology and clinical presentation of SAA, followed by a discussion of traditional treatment
strategies and their limitations. Emphasis will be placed on the evolving role of upfront BMT, including patient selection, donor sources,
conditioning approaches, and expected outcomes. Current evidence comparing upfront transplantation with immunosuppressive
therapy will be examined, along with emerging data supporting the use of matched unrelated donors. It will conclude with practical, case-based discussions to highlight real-world decision-making, management of
complications, and long-term considerations for patients undergoing upfront BMT.

Presenter: Neel Bhatt, MD, Fred Hutchinson Cancer Center

Moderator: Chelsea Honstain, MS, FNP-C, University of Michigan

The Cord Blood Transplant for Non-Malignant Disorders webinar, presented by the ASTCT Cord Blood SIG, was aired on Wednesday, May 20 at 12 p.m. CT/1 p.m. ET. The session consisted of two 25-minute presentations by Dr. Caridad Martinez and Dr. Joanne Kurtzberg, followed by a 10-minute Q&A session.

Session Description:

This webinar provide an overview of the role of cord blood transplantation in the treatment of non-malignant disorders, highlighting its unique advantages as a stem cell source. The first presentation focuses on the use of cord blood transplantation for Severe Combined Immunodeficiency (SCID), including indications, timing, and clinical outcomes. The second presentation addresses cord blood transplantation for Krabbe disease, with emphasis on early intervention, disease modification, and long-term patient outcomes. Together, these talks offer practical insights into patient selection, transplant strategies, and emerging considerations in this evolving field.

Presenters:

Caridad Martinez, MD

Texas Children's Hospital, Baylor College of Medicine; Houston, TX

Joanne Kurtzberg, MD

Duke University School of Medicine; Durham, North Carolina

Moderator:

Alan Bidgoli, DO

Children’s Healthcare of Atlanta, Emory University School of Medicine; Atlanta, GA

Session Learning Objectives:

Upon completion of the activity, participants should be able to:

• Describe the principles and indications of cord blood transplantation in non-malignant disorders, including its advantages compared to other stem cell sources.
• Explain the role of cord blood transplantation in the management of Severe Combined Immunodeficiency (SCID), including patient selection, timing of transplant, and outcomes.
• Summarize the pathophysiology and clinical progression of Krabbe disease and outline how cord blood transplantation modifies disease course when performed early.
• Compare transplant approaches, conditioning regimens, and clinical outcomes between cord blood transplantation for SCID and Krabbe disease to evaluate factors influencing treatment success.

The Medicare FY 2027 IPPS Proposed Rule webinar aired on Thursday, May 14 from 11:00 a.m. – 12:00 p.m. CDT with ASTCT Director of Government Relations, Molly Ford, and the reimbursement and policy advisors to ASTCT from Nimitt Consulting.

The webinar covered multiple CMS proposals for FY 2027, including updates to payment rates for key MS-DRGs for stem cell transplant and CAR-T and other immunotherapies. 

• Proposed increase of approximately $22,000 to the base payment rate for MS-DRG 018 (CAR-T and Other Immunotherapies)
• Proposed increase of approximately $700 to the base payment rate for MS-DRG 014 (Allogeneic Stem Cell Transplant) 
• A substantial proposed increase to the Fixed Loss Outlier Threshold amount
• Applications for New Technology Add-on Payment
• And more! 

Comments can be submitted to CMS via https://www.regulations.gov/docket/CMS-2026-1256 (CMS-1849-P) and are due on or by June 9, 2026.

The ASTCT Pharmacy SIG March 2026 Journal Club aired on Wednesday, March 25. The webinar consisted of two, 30-minute journal club presentations, which included 20 minutes for the presentation and 10 minutes for discussion and a Q & A session. In the March Journal Club session, Drs. Eckstein-Schoemann and Swartz presented two articles related to:

• Orca-T versus allogeneic HCT
• Teclistamab plus daratumumab in relapse or refractory multiple myeloma

Presenters & Articles:

Katarina Eckstein-Schoemann, PharmD

PGY-2 Pharmacy Resident

Duke University Hospital

Article: Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial

Cole Swartz, PharmD

PGY-2 Pharmacy Resident

The John Hopkins Hospital - Department of Pharmacy

Article: Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma

Session Learning Objectives:

Upon completion of the activity, participants should be able to:

• Review current standard graft-versus-host disease (GVHD) prophylaxis following matched-donor allogeneic hematopoietic stem cell transplant (HSCT) and their limitations
• Analyze the efficacy and safety of Orca-T versus tacrolimus/methotrexate in the phase 3 PRECISION-T trial, with focus on chronic GVHD-free survival and non-relapse mortality
• Discuss the potential clinical role of Orca-T, including patient selection, logistical considerations, and implications for future GVHD prophylaxis
• Describe the rationale for combining teclistamab with daratumumab in relapsed/refractory multiple myeloma
  
• Analyze the safety and efficacy of teclistamab-daratumumab when used for relapsed/refractory multiple myeloma
• Identify appropriate candidates for teclistamab-daratumumab combination therapy based on prior treatment exposure, performance status, and disease characteristics

This activity will expire on March 24, 2027.

ACCREDITED PROVIDER

This activity is jointly provided by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT).

In support of improving patient care, this activity has been planned and implemented by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT). The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CREDIT DESIGNATION

Pharmacists

This knowledge-based activity, UAN JA0007204-9999-26-065-H01-P qualifies for 1.0 contact hour (0.10 CEU) of continuing pharmacy education credit. Please submit all evaluations and credit requests no later than 30 days after you complete this activity to ensure your credit fulfillment, as CE credit cannot be awarded past 60 days from the activity date. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service ([email protected]). 

All other healthcare professionals completing this course will be issued a statement of participation.

The full accreditation information for this enduring session can be found here.